Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)

被引：0
|
作者：
Normanno, N. [1 ]
Rachiglio, A. M. [2 ]
Lambiase, M. [2 ]
Fenizia, F. [2 ]
Iannaccone, A. [2 ]
Chicchinelli, N. [1 ]
Morabito, A. [3 ]
Montanino, A. [3 ]
Rocco, G. [4 ]
Galetta, D. [5 ]
Montagna, S. [5 ]
Crino, L. [6 ]
Ludovini, V. [6 ]
Vincenzi, B. [7 ]
Barletta, E. [8 ]
Pinto, C. [9 ]
Ferrau, F. [10 ]
Botti, G. [11 ]
Piccirillo, M. C. [12 ]
Perrone, F. [12 ]
机构：
[1] Fdn Pascale, Ist Nazl Tumori, IRCCS, Cell Biol & Biotherapy Unit, Naples, Italy
[2] Fdn G Pascale, IRCCS, Ist Nazl Tumori, Lab Pharmacogen,CROM, Mercogliano, AV, Italy
[3] Fdn G Pascale, IRCCS, Ist Nazl Tumori, Med Oncol Unit,Thorac Dept, Naples, Italy
[4] Fdn Pascale, IRCCS, Ist Nazl Tumori, Thorac Oncol, Naples, Italy
[5] Ist Tumori Giovanni Paolo II, Dept Med Oncol, Bari, Italy
[6] Santa Maria della Misericordia Hosp, Med Oncol, Perugia, Italy
[7] LIUCBM, Med Oncol, Rome, Italy
[8] Azienda Osped G Rummo, Med Oncol, Benevento, Italy
[9] Azienda Osped Arcispedale Santa Maria Nuova, IRCCS, SC Oncol, Reggio Emilia, Italy
[10] Osped San Vincenzo, Med Oncol, Taormina, Italy
[11] Fdn Pascale, IRCCS, Ist Nazl Tumori, Dipartimento Anat Patol, Naples, Italy
[12] Fdn Pascale, IRCCS, Ist Nazl Tumori, Clin Trial Unit, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1235P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
    Normanno, N.
    Rachiglio, A. M.
    Lambiase, M.
    Fenizia, F.
    Iannaccone, A.
    Chicchinelli, N.
    Morabito, A.
    Rocco, G.
    Galetta, D.
    Montagna, E. S.
    Crino, L.
    Ludovini, V.
    Vincenzi, B.
    Barletta, E.
    Pinto, C.
    Ferrau, F.
    Botti, G.
    Piccirillo, C.
    Perrone, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Arcila, M. E.
    Riely, G. J.
    Zakowski, M. F.
    Kris, M. G.
    Ladanyi, M.
    Pao, W.
    Miller, V. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CO-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND RESPONSE TO EGFR TYROSINE KINASE INHIBITORS (TKIS)
    Barnet, Megan B.
    O'Toole, Sandra
    Horvath, Lisa' G.
    Selinger, Christina
    Yu, Bing
    Trent, Ronald
    Ng, Chiu Chin
    Boyer, Michael J.
    Cooper, Wendy
    Kao, Steven
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 156 - 156
  • [4] Rebiopsy of patients with "acquired resistance" to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Miller, Vincent A.
    Riely, Gregory J.
    Arcila, Maria E.
    Oxnard, Geoffrey
    Zakowski, Maureen F.
    Kris, Mark G.
    Pao, William
    Ladanyi, Marc
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S314 - S314
  • [5] Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) impact on immune microenvironment in non-small cell lung cancer (NSCLC).
    Tang, Jie
    Liu, XiaoLing
    Gong, Youling
    Zhu, Jiang
    Huang, Meijuan
    Ding, Zhenyu
    Yu, Min
    Tie, Yan
    Li, Qiu
    Wang, Yongsheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
    Rachiglio, Anna Maria
    Fenizia, Francesca
    Piccirillo, Maria Carmela
    Galetta, Domenico
    Crino, Lucio
    Vincenzi, Bruno
    Barletta, Emiddio
    Pinto, Carmine
    Ferrau, Francesco
    Lambiase, Matilde
    Montanino, Agnese
    Roma, Cristin
    Ludovini, Vienna
    Montagna, Elisabetta Sara
    De Luca, Antonella
    Rocco, Gaetano
    Botti, Gerardo
    Perrone, Francesco
    Morabito, Alessandro
    Normanno, Nicola
    [J]. CANCERS, 2019, 11 (03):
  • [7] Impact of epidermal growth factor receptor (EGFR) mutations on responsiveness of non-small cell lung cancer (NSCLC) to tyrosine kinase inhibitors (TKIS): Prospective observations
    van Zandwijk, Nico
    Mathy, Alexandre
    de Jong, Daphne
    Baas, Paul
    Burgers, Sjaak
    Nederlof, Petra
    [J]. EJC SUPPLEMENTS, 2006, 4 (06): : 14 - 15
  • [8] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Gelatti, Ana C. Z.
    Drilon, Alexander
    Santini, Fernando C.
    [J]. LUNG CANCER, 2019, 137 : 113 - 122
  • [9] Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
    Mountzios, Giannis
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [10] Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors
    Karachaliou, Niki
    Rosell, Rafael
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 114 - 117
12345